Sensorion (FR0012596468 – ALSEN) a clinical-stage biotech company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announced an update on timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL). Patient recruitment rates from this trial now indicate the data will be available by mid-year 2021, which is later than previously announced.
“The AUDIBLE-S trial is progressing but we are obviously disappointed that the recruitment rate is at a slower pace than our original expectations,” said Nawal Ouzren, CEO of Sensorion.
“An important factor also impacting recruitment in our trial is the reprioritization of emergency room resources due to the current COVID-19 situation. As the epidemic situation is rapidly changing, our revised estimate is for a top-line data readout by mid-year 2021. We will continue to monitor the situation and will provide updates should there be significant changes to this timeline.”
“We are doing our utmost to ensure we can provide the clinical data set as quickly as possible, so that we can define the next steps with SENS-401 within the field of SSNHL and use our scientific know-how and expertise to develop much needed treatments for people suffering from hearing loss disorders,” said Géraldine Honnet, CMO of Sensorion.